Adjuvant Ipilimumab in Melanoma: Future in Doubt

This hugely expensive regimen has now been eclipsed by the checkpoint inhibitor nivolumab, placing the future of adjuvant ipilimumab under question, argues one expert.
Medscape Medical News

http://ift.tt/2y7UggM